Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG (Pegaspargase, Etoposide, Gemcitabine) in NK/T-cell Lymphoma
NCT02705508Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2016
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 2, open-label trial of pegaspargase in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 3 years. Status: unknown.
02
Drugs
pegaspargase
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT02705508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02705508.